/

Amicus Therapeutics, Inc.

FOLD US

FOLD USAmicus Therapeutics, Inc.

United States Composite

10.61

USD

+0.28

(+2.71%)

-0.51EPS Dil.

-20.66P/E

3.12BMarket Cap

Next Earnings

May 8

Held by Insiders

0.75%

Held by Institutions

109.74%

Short % of Float

10.47%

YTD Yield

-0.17%

3Y Yield

17.32%

5Y Yield

-9.54%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

393

394

388

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

287

291

294

Market Capitalization

3,605

3,535

4,166

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

433

463

483

Cash, Cash Equivalents & STI

266

280

286

Accounts Receivable, Net

Inventories

Total Current Liabilities

159

169

168

Payables & Accruals

151

162

111

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

37.89%

21.28%

Net Income, GAAP

-15.17%

14.20%

35.86%

Free Cash Flow

-13.44%

21.85%

54.71%

Total Cash Common Dividend

- -

Total Equity

32.55%

-4.73%

30.08%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

306

2022

329

2023

104

115

399

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.25

-0.19

-0.29

-0.92

2022

-0.30

-0.21

-0.12

-0.19

-0.82

2023

-0.18

-0.15

-0.07

-0.11

-0.51

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Bradley L. Campbell M.B.A.
Full Time Employees: 517
Sector: Healthcare
Industry: Biotechnology
Address: 47 Hulfish Street Princeton NJ United States 08542
CIK: 0001178879
Website: amicusrx.com
Business: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Company News

Zacks
22 days ago
Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?
Yahoo
a month ago
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
Yahoo
a month ago
Director Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD)
Yahoo
2 months ago
Amicus Therapeutics Stock Sees RS Rating Improve To 74

Company Description

CEO: Mr. Bradley L. Campbell M.B.A.
Full Time Employees: 517
Sector: Healthcare
Industry: Biotechnology
Address: 47 Hulfish Street Princeton NJ United States 08542
CIK: 0001178879
Website: amicusrx.com
Business: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.